No, FDA Isn’t Banning BPC-157

The July 2026 briefing document says less than it sounds like it says

By Dr. Shawn Rowland, MD, Founder and CEO of Jase

Every week a patient brings up BPC-157. Sometimes it’s a gym client asking about tendon healing, sometimes it’s someone who found it through a peptide forum for gut issues. So when FDA posted a nearly 70-page briefing document ahead of the Pharmacy Compounding Advisory Committee meeting on July 23 and 24, 2026, I read the whole thing.¹ It’s worth unpacking, because the headline version that will circulate (“FDA moves to ban BPC-157”) is not actually what the document says.

It also helps to know BPC-157 was not singled out. FDA reviewed seven peptides at this meeting, and its scientists recommended against adding all seven to the compounding list.² This is a document about how thin the evidence base is across a whole category, not a verdict aimed at one molecule.

What’s actually being decided

Two compounders, Wells Pharmacy Network and LDT Health Solutions, nominated BPC-157 (and its acetate salt form) for the 503A Bulks List, the list of substances a compounding pharmacy can legally use to make individualized prescriptions. Both nominations were withdrawn. FDA decided to evaluate the peptide anyway, on its own initiative, but narrowed the efficacy review to one specific use: ulcerative colitis. That narrowing matters. The agency explicitly did not evaluate BPC-157 for tendonitis, Crohn’s, or Celiac disease, because the nominators never submitted enough information for those uses to be reviewed at all.¹ So the efficacy question in front of the committee is about ulcerative colitis, not about everything patients are actually using the peptide for.

This is also not happening in a vacuum. BPC-157 spent two years on FDA’s Category 2 list of substances that raise significant safety concerns, came off that list in April 2026 as part of a broader reconsideration of restricted peptides, and now lands in front of this committee.³ The July meeting is one technical step inside a much larger, very public back-and-forth over peptide access.

What FDA actually found

Strip away the regulatory language and the case is this. There is no USP monograph for BPC-157 in either form. The two nominators couldn’t even agree with their own paperwork on whether they were nominating the free base or the acetate salt, and their certificates of analysis didn’t match what they wrote in the nomination¹. For efficacy, FDA found exactly one trial in UC patients, a 53 person rectal enema study that exists only as a conference abstract, with no real detail on inclusion criteria or statistical methods, and no statistically significant benefit over placebo¹. For human safety, the FAERS database returned three case reports, all involving injectable BPC-157. One was confounded by a second peptide the patient was also injecting, one could not be interpreted because almost no information was reported, and one involved a product that also contained TB-500, where the reaction returned when the patient restarted it but could not be pinned to either peptide.¹ Nobody has run a human pharmacokinetic study for oral, subcutaneous, nasal, or transdermal delivery, despite those being the four routes patients are actually using¹.

On the animal side, the picture is more reassuring than the headline suggests. BPC-157 wasn’t mutagenic in Ames assays, didn’t cause birth defects in pregnant rats at any tested dose, and produced no clearly drug-attributable serious events in the small human record that exists.The toxicology read is closer to “we don’t have enough information to rule out risk” than “we found a dangerous compound.”

Where I land on this

I built a telemedicine practice around the idea that patients deserve more access to care, not less. So I want to be precise about where I agree with FDA and where I do not.

The part FDA gets right is the quality question. A substance sold under one name while carrying two different chemical identities, with no monograph and no agreed impurity-testing standard, is a real problem, especially for injectable and nasal products where endotoxin and aggregation risk are genuine. FDA’s recommendation rests mostly here: its scientists call BPC-157 “not well-characterized” and point to missing data on impurities, aggregates, and sterility, not to a finding that the peptide failed.¹ That is a legitimate concern, and I am not going to pretend otherwise.

Here is where I part ways. A quality problem calls for a higher quality bar, not for pushing the substance out of the one channel where quality can be controlled. BPC-157 has been studied since 1993⁴ and has millions of views across social media and peptide forums. That demand is not waiting on a committee vote.

If BPC-157 comes off the 503A list, that demand doesn’t disappear. It moves to the channels FDA isn’t even discussing in this document: direct-to-consumer peptide sellers shipping vials labeled “research use only,” med spas with no physician oversight, and telehealth operations cutting corners on the very COA and purity testing that legitimate compounders are required to provide. The exact impurity and aggregation risk the agency is worried about gets worse, not better, once you push the substance out of a regulated pharmacy and into a supply chain with zero accountability.

If the goal is patient safety, the better path is tightening the quality bar inside the regulated channel: require validated impurity testing, require a real CoA before listing approval, and build a post-market surveillance mechanism through the outsourcing facility reporting structure that already exists. Pulling the substance off the list without a parallel path for legitimate use doesn’t solve the underlying problem. It just moves it somewhere nobody is watching.

What patients and prescribers can actually do:

The committee meets July 23 and 24. If you want your experience on the record, be clear-eyed about the calendar. The window to register to speak at the meeting has closed, and the deadline for written comments to reach the committee before it votes has passed. What is still open: FDA is accepting written comments through July 22 under docket FDA-2025-N-6895 at regulations.gov, and those comments go to the agency as it finalizes its decision after the meeting.⁵ A committee recommendation is not a final rule. The decision is not closed yet, and prescribers with real case experience, along with patients treated through licensed pharmacies, are exactly the input this record is thin on.

Sources:

1. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 (BPC-157 free base and acetate). Docket FDA-2025-N-6895. https://www.fda.gov/media/193343/download
2. FDA, 2026 Meeting Materials, Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/2026-meeting-materials-pharmacy-compounding-advisory-committee
3. FDA interim policy on compounding using bulk drug substances; removal of BPC-157 from the Category 2 list, April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
4. Sikiric P, et al. First description of BPC-157 (gastric pentadecapeptide), 1993; subsequent preclinical literature 1993-2024.
5. Federal Register, Pharmacy Compounding Advisory Committee; Notice of Meeting; docket FDA-2025-N-6895 (comment and registration deadlines). https://www.federalregister.gov/documents/2026/04/16/2026-07361/